Drugs /

nl-201

Back to Drugs List

Overview

NCI Definition [1]:
An interleukin-2 (IL-2) and interleukin-15 (IL-15) receptor agonist with high binding affinity for the common heterodimeric receptor IL-2Rbeta-gamma, which is composed of the IL-2 receptor subunit beta (IL-2Rbeta; CD122) and IL-2 receptor subunit gamma (IL-2Rgamma; common gamma; CD132), and no binding affinity for the IL-2 receptor subunit alpha (IL-2Ralpha; CD25), with potential immunoregulatory and antineoplastic activities. Upon administration, IL-2/IL-15 receptor agonist NL-201 targets and binds to IL-2Rbeta-gamma on natural killer (NK) and T-cells and activates IL-2Rbeta-gamma-mediated signaling. This induces the selective proliferation of CD8+ T-cells and NK cells, enhances tumor cell killing and decreases tumor cell proliferation. NL-201 does not bind to IL-2Ralpha, thereby circumventing both the activation of immunosuppressive regulatory T-cells (Tregs) and the exacerbation of vascular leak syndrome associated with recombinant human IL-2. IL-2 and IL-15 receptors are cytokine receptors that play key roles in the immune response.

Clinical Trials

View Clinical Trials for nl-201

Nl-201 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating nl-201, 1 is phase 1 (1 open).

Kidney carcinoma, malignant solid tumor, and skin carcinoma are the most common diseases being investigated in nl-201 clinical trials [2].

Drug Details

Synonyms [2]:
il-2/il-15 receptor agonist nl-201, interleukin-2/interleukin-15 receptor agonist nl-201, nl 201, nl201
Drug Target(s) [2]:
IL2RA
NCIT ID [1]:
C176866

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.